Sterling’s Omniscan (gadodiamide)
Executive Summary
Non-ionic imaging agent for use with magnetic resonance imaging (MRI) scans expected to be introduced "later this year," Sterling Winthrop Chairman Louis Mattis tells Sept. 3 press briefing. Mattis also reports that the Sterling and Sanofi alliance currently has "over 40 compounds" in development, including six compounds in the areas of cardiovascular disease, imaging, cancer and osteoporosis that the two companies have agreed to co-finance development.